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Daily short intravenous infusions of Interleukin-2 (IL-2)
have been developed to decrease toxicity while maintain-
ing anticancer activity of this agent against kidney cancer.
Such IL-2 schedules have previously been shown to
increase Lymphokine Activated Killer cell (LAK) num-
bers (Quan) and LAK activity (Mitchell). Famotidine may
increase LAK activity by increasing Interleukin-2 interna-
lization by the IL-2 receptor on lymphocytes (Tsunoda).
We treated 15 patients with metastatic clear cell kidney
cancer using IL-2 18 Million IU/M2 intravenously over
15-30 minutes preceded by famotidine 20 mg IV daily for
3 days for 6 consecutive weeks on an outpatient basis.
Cycles were repeated every 8 weeks until disease progres-
sion. Patient characteristics: 7 males/8 females, median
age-59 (range: 28-70), median ECOG performance sta-
tus-1; common metastatic sites: lungs (14), lymph nodes
(9), liver (4), bone (4), and pancreas (4). Prior systemic
therapy: oral TKI (8), Interleukin-2 (6), mTor inhibitor
(2), no prior (3). Prior nephrectomy (9). Most common
toxicities were rigors (13), arthralgia/myalgia (12),
nausea/emesis (11), fever (11), hypotension (11), and con-
stipation (8). All episodes of hypotension were transient
and alleviated with outpatient intravenous fluid. No
patients have required hospitalization due to toxicity of
therapy. There have been no treatment-related deaths.
One complete response (7%) (in lungs lasting 13 months)
and four partial responses (26%) have been seen (total
response rate =33%; 95% CI:15-59%). Responses have
occurred in lungs, liver, lymph nodes, and bone. Median
response duration = 5 months (2-13). Median survival =
13.75 months (3-41 months). Two patients are alive at
35.7+ and 35.2+ months. Dose-dense outpatient
intravenous Interleukin-2 preceded by famotidine has
activity in metastatic clear cell kidney cancer.
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